LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

Home・Aandelen Lijst・SCYNEXIS Inc

SCYNEXIS Inc

Gesloten

0.73 -3.95

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

0.71

Max

0.76

Belangrijke statistieken
By Trading Economics
Inkomsten	-34M -21M
Verkoop	18M 19M
Winstmarge	-114.228
Werknemers	18
EBITDA	-27M -17M

Aanbevelingen
By TipRanks
Aanbevelingen	Buy
12 Maanden Prognose	+354.55% upside

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-13M 65M
Vorige openingsprijs	4.68
Vorige sluitingsprijs	0.73

Technische score

By Trading Central

Vertrouwen

Weak Bullish Evidence

0.9307 / 0.9907 Steun & Weerstand

SCYNEXIS Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

15 mei 2026, 22:47 UTC

Populaire aandelen

Stocks to Watch: Macy's, Delta, UnitedHealth, NextNRG

15 mei 2026, 22:16 UTC

Acquisities, Fusies, Overnames

Canadian Tribunal Gives Keyera, Plains Until Late June to Rebut Bid to Undo Merger

15 mei 2026, 22:00 UTC

Belangrijke Marktbewegers

Delta Air Shares Rise as Berkshire Hathaway Discloses Stake

15 mei 2026, 18:09 UTC

Belangrijke Marktbewegers

Palo Alto Shares Head for Record-High Close, Analysts See Benefits to Identity Security Pivot

15 mei 2026, 16:02 UTC

Winsten

Belangrijke Marktbewegers

Forward Industries Shares Fall on New Debt as Solana Value Drops

15 mei 2026, 14:55 UTC

Belangrijke Marktbewegers

Aardvark Therapeutics Shares Plunge After FDA Hold on ARD-101 New Drug Application

15 mei 2026, 14:43 UTC

Belangrijke Marktbewegers

Chip Stocks Slide After U.S.-China Summit Ends Without Major Tech Deals -- Update

15 mei 2026, 22:17 UTC

Acquisities, Fusies, Overnames

Berkshire Boosted Stake in Alphabet in First Quarter, Bought Delta Air, Sold Visa, Mastercard -- Barrons.com

15 mei 2026, 21:59 UTC

Acquisities, Fusies, Overnames

Stanley Druckenmiller Just Exited Alphabet. TCI Fund Management Is Buying. -- Barrons.com

15 mei 2026, 21:50 UTC

Acquisities, Fusies, Overnames

Berkshire Boosted Stake in Alphabet in First Quarter, Bought Delta Air, Sold Visa, Mastercard -- Barrons.com

15 mei 2026, 21:30 UTC

Acquisities, Fusies, Overnames

Bill Ackman's Pershing Square Bets on Microsoft's AI Ambitions With New Stake -- 4th Update

15 mei 2026, 21:16 UTC

Marktinformatie

Canada Oil Producers Expect Govt Cash Before Building Pathways Project -- Market Talk

15 mei 2026, 20:50 UTC

Marktinformatie

Auto & Transport Roundup: Market Talk

15 mei 2026, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

15 mei 2026, 20:19 UTC

Populaire aandelen

Stocks to Watch Recap: Intel, Nvidia, Amgen, LVMH -- WSJ

15 mei 2026, 19:41 UTC

Acquisities, Fusies, Overnames

SanDisk Stock Is Up 494% This Year. Insiders Are Cashing In on the AI-Fueled Surge. -- Barrons.com

15 mei 2026, 19:35 UTC

Marktinformatie

Oil Futures Settle Higher on Inventory Worries -- Market Talk

15 mei 2026, 19:33 UTC

Marktinformatie

U.S. Natural Gas Futures Rise as Weather Heats Up -- Market Talk

15 mei 2026, 18:35 UTC

Winsten

Xanadu Quantum Revenue Increases Fourfold. Why the Stock Is Falling. -- Barrons.com

15 mei 2026, 17:28 UTC

Marktinformatie

U.S. Oil Rig Count Rises by 5 to 415 -- Market Talk

15 mei 2026, 16:50 UTC

Acquisities, Fusies, Overnames

Microsoft Stock Moves Higher After Ackman Announces New Stake -- WSJ

15 mei 2026, 16:24 UTC

Acquisities, Fusies, Overnames

Bill Ackman's Pershing Square Bets on Microsoft's AI Ambitions With New Stake -- 3rd Update

15 mei 2026, 16:20 UTC

Marktinformatie

Tech, Media & Telecom Roundup: Market Talk

15 mei 2026, 16:20 UTC

Marktinformatie

Auto & Transport Roundup: Market Talk

15 mei 2026, 16:20 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

15 mei 2026, 15:55 UTC

Marktinformatie

Canada's 1Q Rebound Not a Turning Point -- Market Talk

15 mei 2026, 15:20 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

15 mei 2026, 15:20 UTC

Marktinformatie

Silver Plunges on Inflation Worries -- Market Talk

15 mei 2026, 15:20 UTC

Winsten

A Micron and Sandisk Peer Is Coming to U.S. Markets. What to Know About Japan's Kioxia. -- Barrons.com

15 mei 2026, 14:33 UTC

Marktinformatie

Dollar Could Drift Higher as it Retains High-Yielding Status -- Market Talk

Peer Vergelijking

Prijswijziging

SCYNEXIS Inc Prognose

Koersdoel

By TipRanks

354.55% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 3.5 USD 354.55%

Hoogste 4 USD

Laagste 3 USD

Gebaseerd op 2 Wall Street-analisten die 12-maands prijsdoelen bieden voor SCYNEXIS Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

2 ratings

Buy

Hold

Sell

Gebaseerd op 2 analisten die aandelenratings hebben gegeven aan SCYNEXIS Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

0.9307 / 0.9907Steun & Weerstand

Recent bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

There are no events.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over SCYNEXIS Inc

SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases. The company has licensing and collaboration agreements with GlaxoSmithKline Intellectual Property (No. 3) Limited, Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC for the development, manufacture, and commercialization of ibrexafungerp. SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. The company was incorporated in 1999 and is headquartered in Jersey City, New Jersey.